Immune-related adverse events of biological immunotherapies used in COVID-19.

Baracaldo-Santamaría, Daniela; Barros-Arias, Giovanna María; Hernández-Guerrero, Felipe; De-La-Torre, Alejandra; Calderon-Ospina, Carlos-Alberto

Baracaldo-Santamaría, Daniela; Barros-Arias, Giovanna María; Hernández-Guerrero, Felipe; De-La-Torre, Alejandra; Calderon-Ospina, Carlos-Alberto.

Afiliação

Baracaldo-Santamaría D; Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario Bogotá, Bogotá, Colombia.
Barros-Arias GM; Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario Bogotá, Bogotá, Colombia.
Hernández-Guerrero F; Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario Bogotá, Bogotá, Colombia.
De-La-Torre A; Neuroscience Research Group (NEUROS). Neurovitae Center, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Calderon-Ospina CA; Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario Bogotá, Bogotá, Colombia.

Front Pharmacol ; 13: 973246, 2022.

Article em En | MEDLINE | ID: mdl-36091800

Palavras-chave

COVID-19; adverse reactions; monoclonal abs; sarilumab; siltuximab; sotrovimab; tocilizumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google